Article
Clinical and imaging markers in premotor LRRK2 G2019S mutation carriers.
Parkinsonism & related disorders - 1 Oct 2015
Vilas Dolores, Ispierto Lourdes, Álvarez Ramiro, Pont-Sunyer Claustre, Martí María José, Valldeoriola Francesc, Compta Yaroslau, de Fabregues Oriol, Hernández-Vara Jorge, Puente Víctor, Calopa Matilde, Jaumà Serge, Campdelacreu Jaume, Aguilar Miquel, Quílez Pilar, Casquero Pilar, Lomeña Francisco, Ríos José, Tolosa Eduardo
Abstract excerpt
BACKGROUND: Substantia nigra hyperechogenicity (SN+) has been proposed as a risk marker of Parkinson's disease (PD). Asymptomatic LRRK2 mutation carriers (aLRRK2+), at high risk for developing PD, provide an opportunity for the study of preclinical biomarkers. OBJECTIVE: To assess SN echogenicity and other echographic features in LRRK2 G2019S carriers and their clinical and imaging correlates. METHODS:...
Topics
- Adult
- Aged
- Aged, 80 and over
- Dopamine Plasma Membrane Transport Proteins
- Female
- Genetic Markers
- Heterozygote
- Humans
- Leucine-Rich Repeat Serine-Threonine Protein Kinase-2